Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant. - Wikidata - wikimedia - TriplyDB

Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.

Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.

http://www.wikidata.org/entity/Q37828009

about

Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes

P2860

Q37504482-46EBCC25-E797-4433-ACD2-37CAECC7E83D

P2860

Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.

http://www.wikidata.org/entity/Q37828009

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@en

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@nl

type

label

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@en

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@nl

prefLabel

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@en

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@nl

P1433

Q37828009-FEE0B6ED-EA91-4106-ADC0-304BA9FE951D

P1476

Q37828009-9B1ABDD2-8F65-4AE1-AD96-6D6CB1F64234

P2093

Q37828009-B21E61AC-039D-4714-8918-DF78A1B32C50

Q37828009-C3D83E6D-0484-4556-B72E-4BB611D9D756

Q37828009-E0DCCBDA-2E96-4E63-8E00-034BBF7EF4ED

Q37828009-E7C5F760-BDF2-43A5-8691-02FD39FE4000

Q37828009-EA549154-BF27-42F9-BCCE-D828EC37406F

P2860

Q37828009-10B693A3-5698-458B-9A67-A73E8D741A86

Q37828009-1FB972E6-95C3-4D8D-A27C-FECBF02CEE95

Q37828009-3E29530B-1603-4B39-B0DC-054E137F6D85

Q37828009-4059FB72-7337-4884-97F1-953909E08B1C

Q37828009-579F5FC1-8D22-4D2F-93A2-B5FC41919FD4

Q37828009-691960E1-F6E7-4F2F-9CD8-A7C163F4A687

Q37828009-7F7E9CBB-1C42-448B-B7BA-799A6702B5F6

Q37828009-AA36C616-A012-4954-8CB4-A8F32A9F11CC

Q37828009-AC36AC48-222D-47BC-9400-B788E82581BC

Q37828009-E0DF9DF4-C566-4D2C-8B2E-773CA3D579CC

P304

Q37828009-53116BEF-6042-4631-B575-6C0F3BE9041C

P31

Q37828009-914C7D86-4E6D-4E71-9C9E-E1B099C66AB4

P356

Q37828009-240C018A-58E6-4D1B-BD59-B8F4E48FD816

P433

Q37828009-5D6ED603-28F5-47F2-8EA9-9A410EBEE89A

P478

Q37828009-CEF0736C-24D6-427E-AE2C-3657654D295E

P577

Q37828009-93FC5309-E085-438A-83B9-B747A1D26060

P698

Q37828009-F00C0BF7-1EE9-4E48-825C-9AD89CC256D2

P356

1078155210392616

P1433

Journal of Oncology Pharmacy Practice

P1476

Once daily busulfan cyclophosp ...... opoietic stem cell transplant.

@en

P2093

Bradley Smith

http://www.w3.org/2001/XMLSchema#string

C F LeMaistre

http://www.w3.org/2001/XMLSchema#string

Carlos Bachier

http://www.w3.org/2001/XMLSchema#string

Julia A LeMaistre

http://www.w3.org/2001/XMLSchema#string

Paul J Shaughnessy

http://www.w3.org/2001/XMLSchema#string

P2860

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.

Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

P304

17-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155210392616

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21228086

http://www.w3.org/2001/XMLSchema#string